Analyst Jasper Hellweg sets a $1,550 price target for Eli Lilly, indicating a potential 12.9% gain from its current trading price of $1,373. The pharmaceutical giant reported robust Q3 2026 results, with revenue soaring 39% to $24.40 billion and adjusted earnings reaching $7.48 per share,…
Eli Lilly (NYSE: LLY) receives an increased price target from Goldman Sachs, signaling potential upside in its stock performance. The pharmaceutical giant is a key player in the competitive and rapidly expanding weight-loss drug market, facing rivalry from Novo Nordisk (NYSE: NVO). Despite strong…
Every article on every company, fresh through the day, plus search for any ticker. Pop in your email to unlock it.
You'll get Gro's newsletter too. Leave any time in one click.
Articles from Financial Modeling Prep.
